ContraFect CFRX Stock
ContraFect Price Chart
ContraFect CFRX Financial and Trading Overview
ContraFect stock price | 0.23 USD |
Previous Close | 1.98 USD |
Open | 1.96 USD |
Bid | 0 USD x 800 |
Ask | 0 USD x 1000 |
Day's Range | 1.91 - 2.05 USD |
52 Week Range | 0.9 - 292.8 USD |
Volume | 453.07K USD |
Avg. Volume | 4.18M USD |
Market Cap | 7.16M USD |
Beta (5Y Monthly) | 0.419366 |
PE Ratio (TTM) | N/A |
EPS (TTM) | 0 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 5 USD |
CFRX Valuation Measures
Enterprise Value | -3960656 USD |
Trailing P/E | N/A |
Forward P/E | -0.52000004 |
PEG Ratio (5 yr expected) | -0.02 |
Price/Sales (ttm) | N/A |
Price/Book (mrq) | N/A |
Enterprise Value/Revenue | N/A |
Enterprise Value/EBITDA | 0.08 |
Trading Information
ContraFect Stock Price History
Beta (5Y Monthly) | 0.419366 |
52-Week Change | -99.22% |
S&P500 52-Week Change | 20.43% |
52 Week High | 292.8 USD |
52 Week Low | 0.9 USD |
50-Day Moving Average | 1.59 USD |
200-Day Moving Average | 7.51 USD |
CFRX Share Statistics
Avg. Volume (3 month) | 4.18M USD |
Avg. Daily Volume (10-Days) | 3.54M USD |
Shares Outstanding | 3.67M |
Float | 3.65M |
Short Ratio | 0.78 |
% Held by Insiders | 1.52% |
% Held by Institutions | 8.94% |
Shares Short | 160.25K |
Short % of Float | 4.37% |
Short % of Shares Outstanding | 4.37% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor | 1:80 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | 0% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -81.22% |
Return on Equity (ttm) | -345.23% |
Income Statement
Revenue (ttm) | N/A |
Revenue Per Share (ttm) | N/A |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | N/A |
EBITDA | -49612000 USD |
Net Income Avi to Common (ttm) | -46367000 USD |
Diluted EPS (ttm) | -974.44 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 13.89M USD |
Total Cash Per Share (mrq) | 3.79 USD |
Total Debt (mrq) | 2.77M USD |
Total Debt/Equity (mrq) | N/A |
Current Ratio (mrq) | 0.901 |
Book Value Per Share (mrq) | -2.003 |
Cash Flow Statement
Operating Cash Flow (ttm) | -43005000 USD |
Levered Free Cash Flow (ttm) | -17170000 USD |
Profile of ContraFect
Country | United States |
State | NY |
City | Yonkers |
Address | 28 Wells Avenue |
ZIP | 10701 |
Phone | 914 207 2300 |
Website | https://www.contrafect.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 23 |
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also developing CF-296, an osteomyelitis and PJI which is in preclinical trailers for the treatment of joint infections. In addition, the company developing Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. Further, It develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.
Q&A For ContraFect Stock
What is a current CFRX stock price?
ContraFect CFRX stock price today per share is 0.23 USD.
How to purchase ContraFect stock?
You can buy CFRX shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for ContraFect?
The stock symbol or ticker of ContraFect is CFRX.
Which industry does the ContraFect company belong to?
The ContraFect industry is Biotechnology.
How many shares does ContraFect have in circulation?
The max supply of ContraFect shares is 0.
What is ContraFect Price to Earnings Ratio (PE Ratio)?
ContraFect PE Ratio is now.
What was ContraFect earnings per share over the trailing 12 months (TTM)?
ContraFect EPS is 0 USD over the trailing 12 months.
Which sector does the ContraFect company belong to?
The ContraFect sector is Healthcare.
ContraFect CFRX included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 17601.05 USD — |
+0.87
|
8.38B USD — | 17181.27 USD — | 17716.52 USD — | — - | 8.38B USD — |
NASDAQ Capital Market Composite RCMP | 101.28 USD — |
+1.47
|
— — | 98.06 USD — | 101.88 USD — | — - | — — |
NASDAQ HealthCare IXHC | 942.47 USD — |
+1.43
|
— — | 920.56 USD — | 943.62 USD — | — - | — — |
NASDAQ Composite Total Return I XCMP | 21542.13 USD — |
+0.87
|
— — | 21028.39 USD — | 21683.46 USD — | — - | — — |
- {{ link.label }} {{link}}